ClinicalTrials.gg
CompletedNCT03125746Updated Nov 19, 2026

A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

A Phase 1 interventional study of LXI-15029 and LXI-15029+Exemestane in Advanced Breast Cancer, sponsored by Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Phase 1, Interventional, and Treatment

How we know · 7 judgments

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.

Enrollment
90th of 101
24 · median 123
Started
2017
with 3 others
Phase 1
Only one
of the 103
Registered
69th of 103
by date

Among the 103 studies testing exemestane in Breast Neoplasms, this one is the 90th largest by enrollment of the 101 interventional ones that give a count, is one of 4 that started in 2017, is the only one in phase 1, and was the 69th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About exemestane

exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing exemestane in Breast Neoplasms, or all of them as a file.
02

Study summary

1. To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose (MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese postmenopausal patients with metastatic or locally advanced breast cancer with estrogen receptor (+) and human epidermal growth factor receptor 2 (-) in combined with Exemestane period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy with Exemestane.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Monotherapy Period

    1. Patients with signed written form;
    2. Chinese man or woman, aged 18 to 65 years old;
    3. Patient with or cytologically confirmed, advanced solid tumor after failure of standard of care or without standard of care;
    4. Patients must have at least one as defined by v1.1 (during dose escalation phase,no measurable lesion as defined by RECIST v1.1 but evaluable lesion could also been enrolled);
    5. Expected survival no less than 12 weeks;
    6. (USA) Performance Status 0 to 1;
    7. Patient of (regardless of man or woman) who is willing to take measures from signature of the informed consent form to 3 months after the last dose of product. Negative serum pregnancy test within 7 days prior to the planned first dose of investigational product for female patient of childbearing potential;
    8. Have the ability to communicate with study staff, understand and comply with all the study requirements;
  • Combined with Exemestane period

    1. Patients with signed written informed consent form;
    2. Chinese patients aged women to 65 years old;
    3. Postmenopausal patient;
    4. Histologically or cytologically confirmed or locally advanced breast cancer that is not suitable for surgery or radiotherapy;
    5. Estrogen receptor (+), defined as tumor cells with estrogen receptor (+) ≥1% in immunohistochemistry;
    6. -negative (Human epithelial growth factor receptor 2-negative) tumor;
    7. Measurable lesions in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;
    8. Expected survival no less than 12 weeks;
    9. Eastern Cooperative Oncology Group (USA) Performance Status 0 to 1;
    10. Have the ability to communicate with study staff, understand and comply with all the study requirements;

Exclusion criteria

Exclusion Criteria:

  • Monotherapy Period:

    1. Previous antitumor therapy or any surgical operation within 4 weeks prior to administration of the first dose of study drug;
    2. Treatment with myeloid hematopoietic growth factor within 2 weeks prior to use of product;
    3. Patients receiving or agents within 4 weeks prior to administration of the first dose of study drug;
    4. Use of potent-to-moderate cytochrome metabolism enzyme inhibitor and inducer prior to treatment or during ;
    5. Known allergy to LXI-15029 or similar products (mammalian target of rapamycin (mTOR) inhibitor or dual mTOR inhibitor) or other components of LXI-15029;
    6. Previous or receiving of PI3K or mTOR inhibitors (e.g., BKM120, everolimus, AZD8055 or AZD2014, etc.);
    7. History, symptoms or signs of spinal compression, or meningeal , or manifestations of edema or progression in radiology;
    8. History of other tumors within 5 years, except cured carcinoma in situ of cervix or cutaneous basal cell carcinoma;
    9. The toxicity induced by treatment unable to be recovered or stabilized to grade 1 or below except alopecia (common terminology criteria on adverse event version 4.03 ( 4.03));
    10. Hemotology and coagulation abnormal defined in protocol;
    11. Hepatic function abnormal defined in protocol;
    12. Renal function abnormal defined in protocol;
    13. Cholesterol > 300 mg/dl or 7.75 mmol/L, and/or triglyceride > 2.5 × ;
    14. Previous history of type 1 or 2 diabetes, or abnormal fasting blood glucose >126 mg/dL(>7 mmol/L) at screening;
    15. Cardiovascular system diseases;
    16. Patients with active upper peptic ulcer, nausea and vomiting, or other conditions that were known to affect absorption, distribution, metabolism or elimination of drugs;
    17. Patients with chronic obstructive emphysema, pulmonary fibrosis or pneumonia that could significantly affect pulmonary function at discretion of the investigator;
    18. Infectious Diseases defined in protocol;
    19. Judged by the investigator, any other serious or uncontrolled acute or chronic disease, or laboratory abnormality (including but not limited to cardiovascular, hepatic and renal, as well as neuromuscular system), and alcohol consumption, drug abuse that could possibly increase the risk for study or interfere with study conduction and result analysis;
    20. Pregnant or lactating women;
    21. Previous enrollment in this study or participation in this investigational therapy;
    22. Participation in other clinical study during the last 30 days prior to Visit 1
    23. At discretion of the Investigator, the patient is unsuitable for participation in this study for any reasons;
    24. Patient of poor compliance.
  • Combined with Exemestane period

    1. Previous antitumor therapy or any surgical operation within 4 weeks prior to administration of the first dose of study drug;
    2. Treatment with myeloid hematopoietic growth factor within two weeks prior to use of investigational product;
    3. Patients receiving corticosteroids or immunosuppressive agents within 4 weeks prior to administration of the first dose of study drug;
    4. Use of potent-to-moderate cytochrome metabolism enzyme CYP3A4 inhibitor and inducer prior to treatment or during washout period
    5. Previous use of Exemestane tablet;
    6. Known allergy to LXI-15029 or similar products (mTOR inhibitor or dual mTOR inhibitor) or other component of LXI-15029;
    7. Previous or receiving of PI3K or mTOR inhibitors (e.g., BKM120, everolimus, AZD8055 or AZD2014, etc.;
    8. Visceral crisis of breast cancer, not suitable for endocrine therapy;
    9. Inflammatory breast cancer;
    10. History, symptoms or signs of spinal compression, brain metastasis or meningeal metastasis, or manifestations of edema or progression in radiology;
    11. History of other tumors within 5 years, except cured carcinoma in situ of cervix or cutaneous basal cell carcinoma;

      Exclusion criteria on concomitant disease and organ function:

    12. The toxicity induced by treatment unable to be recovered or stabilized to grade 1 or below except alopecia (CTCAE 4.03);
    13. Hemotology and coagulation abnormal defined in protocol;
    14. Hepatic function abnormal defined in protocol;
    15. Renal function abnormal defined in protocol;
    16. Cholesterol > 300 mg/dl or 7.75 mmol/L, and/or triglyceride > 2.5 × ULN;
    17. Previous history of type 1 or 2 diabetes, or abnormal fasting blood glucose >126 mg/dL(>7 mmol/L) at screening;
    18. Cardiovascular system abnormal defined in protocol;
    19. Patients with active upper peptic ulcer, refractory nausea and vomiting, or other conditions that were known to affect absorption, distribution, metabolism or elimination of drugs;
    20. Patients with chronic obstructive emphysema, pulmonary fibrosis or pneumonia that could significantly affect pulmonary function at discretion of the investigator;
    21. Infectious Diseases defined in protocol;
    22. Judged by the investigator, any other serious or uncontrolled acute or chronic disease, or laboratory abnormality, and alcohol consumption, drug abuse that could possibly increase the risk for study or interfere with study conduction and result analysis;
    23. Previous enrollment in this study or participation in this investigational therapy;
    24. Participation in other clinical study during the last 30 days prior to Visit 1
    25. At discretion of the Investigator, the patient is unsuitable for participation in this study for any reasons;
    26. Patient of poor compliance.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LXI-15029

    Drug: LXI-15029

  • Experimental
    LXI-15029+Exemestane

    Drug: LXI-15029+Exemestane

Interventions

  • DrugLXI-15029

    The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.

  • DrugLXI-15029+Exemestane

    Drug page: ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    To evaluate the safety and tolerability of LXI-15029 through evaluation of the incidence and severity of adverse event (Common Terminology Criteria for Adverse Events Version 4.03 (CTCAE, 4.03))

    Time frame: When subject complete 1 cycle (28 days) treatment with safety and tolerability assessment by investigators.

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Characterising the pharmacokinetics (PK) profile of LXI-15029

    Time frame: When subject complete 1 cycle (28 days) treatment

  2. Area Under the Curve (AUC)

    Characterising the pharmacokinetics (PK) profile of LXI-15029

    Time frame: When subject complete 1 cycle (28 days) treatment

  3. Tmax

    Characterising the pharmacokinetics (PK) profile of LXI-15029

    Time frame: When subject complete 1 cycle (28 days) treatment

Other outcomes

  1. Best objective response

    Best Objective Response per Response Evaluation Criteria in Solid Tumours Criteria (RECIST) 1.1 for target and non target lesions assessed by CT, MRI or X-ray; Complete Response (CR), Disappearance of all target lesions since baseline; Partial Response (PR), At least a 30 percent decrease in the sum of diameters of target lesions; Progressive Disease (PD), At least a 20 percent increase in the sum of diameters of target lesions and an absolute increase of at least 5mm

    Time frame: Estimated to be up to 6 months

  2. Progression-free survival (PFS)

    Duration from treatment start to the time of disease progression or death.

    Time frame: Estimated to be up to 6 months

07

Study locations

1 site
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Publications

  • Wang J, Gui L, Mu Y, Wang J, Chi Y, Liu Z, Li Q, Xu B. Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors. BMC Cancer. 2023 Dec 6;23(1):1200. doi: 10.1186/s12885-023-11578-8. PubMed 38057772 ↗
  • Zhang Q, Zhang Y, Chen Y, Qian J, Zhang X, Yu K. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clin Cancer Res. 2019 Jun 15;25(12):3630-3642. doi: 10.1158/1078-0432.CCR-18-2548. Epub 2019 Feb 22. PubMed 30796032 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Jul 2021, 49 months.

Of 390 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 49 months is above that.

Counting every sponsor, half of 763 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Oct 2021 → Jul 2021 and completion Oct 2021 → Jul 2021.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 24, 2017
StartActual
Jun 12, 2017
Primary completionActual
Jul 21, 2021was Oct 2021
CompletionActual
Jul 21, 2021was Oct 2021
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 19, 2026
Primary completion
Oct 28, 2021→Jul 21, 2021 (actual)
Nov 19, 2026
Study completion
Oct 28, 2021→Jul 21, 2021 (actual)
Nov 19, 2026
Enrollment
72 (estimated)→24 (actual)
Nov 19, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38057772 ↗
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38057772 ↗
    Primary completion Oct 28, 2021→Jul 21, 2021 (now actual)
    Study completion Oct 28, 2021→Jul 21, 2021 (now actual)
    Enrollment 72 (estimated)→24 (actual)
    + 4 other changes: verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03125746
Lead sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Responsible party
Sponsor
First posted
Apr 24, 2017
Start date
Jun 12, 2017
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Last update
Nov 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Exemestane

Start the discussion